|Mr. J. Scott Wolchko||Founder, CEO, Pres & Director||850.5k||1.73M||1970|
|Dr. Daniel D. Shoemaker||Chief Scientific Officer||525.94k||806.74k||1968|
|Ms. Cindy R. Tahl||Gen. Counsel & Corp. Sec.||525.94k||1M||1973|
|Dr. Bahram Valamehr Ph.D.||Chief Devel. Officer||525.94k||N/A||1977|
|Mr. Edward J. Dulac III||CFO & Principal Accounting Officer||N/A||N/A||1975|
|Dr. Wen Bo Wang||Sr. VP of Technical Operations||N/A||N/A||N/A|
|Mr. Jim Beitel M.B.A.||Sr. VP of Corp. Devel.||N/A||N/A||N/A|
|Dr. Sarah Cooley||Sr. VP of Clinical Translation||N/A||N/A||N/A|
|Dr. Yu-Waye Chu M.D.||Sr. VP of Clinical Devel.||N/A||N/A||N/A|
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Fate Therapeutics, Inc.’s ISS Governance QualityScore as of January 22, 2021 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 9.